The content on this site is intended for healthcare professionals only
Dr Marlies Reimers presented data at a press confernece during the 2013 European Cancer Confernece in Amsterdam about how aspirin improves survival in patients diagnosed with colon cancer.
Although previous research has shown that taking low dose aspirin after being diagnosed with colon cancer improves patient outcome, the reasons why this happens remain unknown.
The new research has shown that aspirin improves outcome in patients whose tumour cells express a specific protein on their surface; the protein is known as Human Leukocyte Antigen class I (HLA class I), a cell-surface protein produced by a collection of genes involved in the functioning of the immune system.
The results mean that HLA class I could be used in the future to predict whether or not a patient would benefit from aspirin.
Read more on ecancerNews
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Research highlights in gastrointestinal tumours
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Immunotherapy significantly increases the number of patients free from bowel cancer
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
